#Alzheimer's #ImmunoBrain #IBC-Ab002

ImmunoBrain's Pioneering Research in Alzheimer's

ImmunoBrain, a biopharmaceutical company specializing in immunotherapy solutions for neurodegenerative diseases, unveiled significant clinical findings during the Alzheimer’s & Parkinson’s Diseases Conference (AD/PD™) 2026 held in Copenhagen, Denmark. The spotlight was on the company’s innovative treatment approach for Alzheimer’s disease, specifically their immune checkpoint therapy IBC-Ab002, presented by lead investigator Professor Catherine J. Mummery.

The Clinical Study Overview

The Phase 1b trial, denoted as IBC-01-01, was a rigorous, randomized, double-blind, placebo-controlled study involving 40 early-stage Alzheimer's patients across multiple sites in the U.K., Netherlands, and Israel. The primary focus of the trial was to assess safety, tolerability, and pharmacokinetics, while also exploring the central nervous system engagement through Alzheimer-related biomarkers over a 12-month period.

Notably, the clinical trial reported a favorable safety profile with no serious adverse effects linked to the treatment. Moreover, no instances of amyloid-related imaging abnormalities (ARIA) were observed, affirming the therapy's potential in addressing one of the major concerns in Alzheimer's treatment. Biomarker analysis for Neurogranin, total-Tau, and pTau181 at a dosage of 30 mg/kg compared to a placebo hinted at possible neuronal protection, stirring optimism among researchers and clinicians alike.

Insights from Professor Catherine J. Mummery

Professor Mummery emphasized the dire need for effective disease-modifying therapies in Alzheimer's disease.